Scilex Holding (SCLXW) Current Deferred Revenue (2022 - 2026)
Scilex Holding (SCLXW) recorded quarterly Current Deferred Revenue of $398000.0 in Q1 2026, down 2.21% quarter-over-quarter from $407000.0 in Q4 2025, and down 8.92% on a YoY basis from $437000.0 in Q1 2025.
Scilex Holding (SCLXW) Current Deferred Revenue (2022 - 2026) Analysis & Trends
Scilex Holding's Current Deferred Revenue history runs 5 years deep, the most recent figure standing at $398000.0 for Q1 2026.
- In Q1 2026, Current Deferred Revenue fell 8.92% year-over-year to $398000.0; the TTM figure through Mar 2026 stood at $398000.0 (down 8.92% YoY), while the FY2025 annual figure was $407000.0, down 8.95% from the prior year.
- Current Deferred Revenue was $398000.0 for Q1 2026 at Scilex Holding, down from $407000.0 in the prior quarter.
- In the past five years, Current Deferred Revenue ranged from a high of $516000.0 in Q2 2023 to a low of $264000.0 in Q4 2022.
- Historically, Current Deferred Revenue has averaged $436071.4 across 5 years, with a median of $442000.0 in 2024.
- The sharpest annual moves came in 2023 and 2024: Current Deferred Revenue surged 85.98% in 2023, then retreated 9.11% in 2024.
- A 5-year view of Current Deferred Revenue shows it stood at $264000.0 in 2022, then soared by 85.98% to $491000.0 in 2023, then declined by 8.96% to $447000.0 in 2024, then fell by 8.95% to $407000.0 in 2025, then declined by 2.21% to $398000.0 in 2026.
- The last three Current Deferred Revenue figures came in at $398000.0 (Q1 2026), $407000.0 (Q4 2025), and $417000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Gsk | 93,699,046.73 Bn | 93,699,041.77 Bn | 7.76 Bn |
| 2 | Eli Lilly | 1,012.06 Bn | 1,006.77 Bn | 16.22 Bn |
| 3 | Johnson & Johnson | 560.67 Bn | 538.62 Bn | 15.96 Bn |
| 4 | AbbVie | 402.20 Bn | 392.85 Bn | 10.78 Bn |
| 5 | Merck | 298.59 Bn | 292.94 Bn | 12.09 Bn |
| 6 | Amgen | 188.77 Bn | 176.74 Bn | 5.87 Bn |
| 7 | Gilead Sciences | 160.22 Bn | 152.49 Bn | 5.52 Bn |
| 8 | Pfizer | 148.19 Bn | 135.42 Bn | -1.21 Bn |
| 9 | Bristol Myers Squibb | 116.72 Bn | 106.26 Bn | 8.07 Bn |
| 10 | Scilex Holding | - | - | 4.15 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 398,000.00 |
| Dec 31, 2025 | 407,000.00 |
| Sep 30, 2025 | 417,000.00 |
| Jun 30, 2025 | 427,000.00 |
| Mar 31, 2025 | 437,000.00 |
| Dec 31, 2024 | 447,000.00 |
| Sep 30, 2024 | 458,000.00 |
| Jun 30, 2024 | 469,000.00 |
| Mar 31, 2024 | 480,000.00 |
| Dec 31, 2023 | 491,000.00 |
| Sep 30, 2023 | 503,000.00 |
| Jun 30, 2023 | 516,000.00 |
| Mar 31, 2023 | 391,000.00 |
| Dec 31, 2022 | 264,000.00 |